Parthiena M Keddis - JoVE Visualize

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

Expert Opinion on Therapeutic Patents|June 23, 2026

An updated patent review of dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors (2020-present)Mennatallah Abdallah, Parthiena M Keddis, Trevina M Keddis, et al.

European Journal of Medicinal Chemistry|May 6, 2026

Benzothiophene nucleus in target-directed anti-cancer drug discoveryPatrick M Maximous, Michael Emad, Parthiena M Keddis, et al.

European Journal of Medicinal Chemistry|February 13, 2025

From Dyrk1A inhibitors to a novel class of antiviral agents: Targeting Enterovirus EV-A71 with 2-aryl-substituted thiophene scaffoldsParthiena M Keddis, Tuong-Khanh My Tu, Hugo Scherer, et al.

Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

Expert Opinion on Therapeutic Patents|June 23, 2026

An updated patent review of dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors (2020-present)Mennatallah Abdallah, Parthiena M Keddis, Trevina M Keddis, et al.

European Journal of Medicinal Chemistry|May 6, 2026

Benzothiophene nucleus in target-directed anti-cancer drug discoveryPatrick M Maximous, Michael Emad, Parthiena M Keddis, et al.

European Journal of Medicinal Chemistry|February 13, 2025

From Dyrk1A inhibitors to a novel class of antiviral agents: Targeting Enterovirus EV-A71 with 2-aryl-substituted thiophene scaffoldsParthiena M Keddis, Tuong-Khanh My Tu, Hugo Scherer, et al.

Pageof 1